share_log

The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More

The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More

生物技术未来一周(6月5日至11日):Adcom对Novavax的测试、ASCO的演讲、Enzo Biochem的收益等
Benzinga Real-time News ·  2022/06/06 04:10
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended.
生物科技股与大盘一起逆转走势,截至6月3日的一周收盘走低。因此,该行业的精益运行得到了延长。
Genocea Biosciences, Inc. (NASDAQ:GNCA), which announced on May 24 plans to wind down of operations, continued to see weakness, ending the week down over 66%. The company is awaiting delisting of its stock from Nasdaq.
Genocea生物科学公司纳斯达克(Sequoia Capital:GNCA)5月24日宣布计划逐步关闭业务,继续表现疲软,本周收盘时跌幅超过66%。该公司正在等待其股票从纳斯达克退市。
Aeglea Biotherapeutics, Inc. (NASDAQ:AGLE) shares also came under intense selling pressure after it announced the Food and Drug Administration's decision to issue a refusal-to-file letter for its Arginase 1 deficiency treatment candidate.
Aeglea BioTreateutics公司纳斯达克(Standard Chartered Bank:AGLE)宣布美国食品和药物管理局(FDA)决定拒绝为其精氨酸酶1缺乏症候选药物出具拒绝备案函后,其股价也面临巨大的抛售压力。
The week witnessed some activity on the...
这一周见证了并...

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发